{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:35:12Z","timestamp":1787236512412,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to evaluate if optimization by maximizing QRS duration (QRSd) reduction is feasible in an all-comer cardiac resynchronization therapy (CRT) population, and if reduced, QRSd is associated with a better clinical outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with LBBB receiving CRT implants during the period 2015\u20132020 were retrospectively evaluated. Implants from 2015\u20132017 were designated as controls. Starting from 2018, an active 12-lead electrogram-based optimization of QRSd reduction was implemented (intervention group). QRSd reduction was evaluated in a structured way at various device AV and VV settings, aiming to maximize the reduction. The primary endpoint was a composite of heart failure hospitalization or death from any cause.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 254 patients were followed for up to 6 years (median 2.9 [1.8\u20134.1]), during which 82 patients (32%) reached the primary endpoint; 53 deaths (21%) and 58 (23%) heart failure hospitalizations. Median QRS duration pre-implant was 162 ms [150\u2013174] and post-implant 146ms [132\u2013160]. Mean reduction in QRS duration was progressively larger for each year during the intervention period, ranging from \u2212 9.5ms in the control group to \u2212 24 in the year 2020 (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005). QRS reduction &gt; 14 ms (median value) was associated with a lower risk of death or heart failure hospitalization (adjusted HR 0.54 [0.29\u20130.98] (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Implementing a general strategy of CRT device optimization by aiming for shorter QRS duration is feasible in a structured clinical setting and results in larger reductions in QRS duration post-implant. In patients with a larger QRS reduction, compared to those with a smaller QRS reduction, there is an association with a better clinical outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s10840-022-01463-y","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T01:02:49Z","timestamp":1673398969000},"page":"1799-1806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Maximizing QRS duration reduction in contemporary cardiac resynchronization therapy is feasible and shorter QRS duration is associated with better clinical outcome"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-6637","authenticated-orcid":false,"given":"Rasmus","family":"Borgquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Marinko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyotr G","family":"Platonov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzma","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"M\u00f6rtsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"issue":"15","key":"1463_CR1","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539\u201349.","journal-title":"N Engl J Med"},{"issue":"35","key":"1463_CR2","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","volume":"42","author":"M Glikson","year":"2021","unstructured":"Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by the task force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) with the special contribution of the European Heart Rhythm Association (EHRA). Eur Heart J. 2021;42(35):3427\u2013520.","journal-title":"Eur Heart J"},{"issue":"5","key":"1463_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10741-019-09839-5","volume":"25","author":"G Bazoukis","year":"2020","unstructured":"Bazoukis G, Naka KK, Alsheikh-Ali A, et al. Association of QRS narrowing with response to cardiac resynchronization therapy-a systematic review and meta-analysis of observational studies. Heart Fail Rev. 2020;25(5):745\u201356.","journal-title":"Heart Fail Rev"},{"issue":"9","key":"1463_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jacc.2008.11.024","volume":"53","author":"W Mullens","year":"2009","unstructured":"Mullens W, Grimm RA, Verga T, et al. Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol. 2009;53(9):765\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"1463_CR5","doi-asserted-by":"crossref","unstructured":"Varma N, O'Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7(3).","DOI":"10.1161\/JAHA.117.007489"},{"issue":"8","key":"1463_CR6","first-page":"e382","volume":"140","author":"FM Kusumoto","year":"2019","unstructured":"Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC\/AHA\/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. Circulation. 2019;140(8):e382\u2013482.","journal-title":"Circulation."},{"issue":"4","key":"1463_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1161\/hc0402.102975","volume":"105","author":"MD Cerqueira","year":"2002","unstructured":"Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105(4):539\u201342.","journal-title":"Circulation."},{"issue":"9","key":"1463_CR8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.hrthm.2013.07.007","volume":"10","author":"D Birnie","year":"2013","unstructured":"Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial. Heart Rhythm. 2013;10(9):1368\u201374.","journal-title":"Heart Rhythm"},{"issue":"6","key":"1463_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ahj.2010.02.034","volume":"159","author":"WT Abraham","year":"2010","unstructured":"Abraham WT, Gras D, Yu CM, Guzzo L, Gupta MS. Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: the frequent optimization study using the QuickOpt Method (FREEDOM) trial. Am Heart J. 2010;159(6):944\u2013948 e941.","journal-title":"Am Heart J"},{"issue":"6","key":"1463_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.amjcard.2006.04.017","volume":"98","author":"N Kedia","year":"2006","unstructured":"Kedia N, Ng K, Apperson-Hansen C, et al. Usefulness of atrioventricular delay optimization using Doppler assessment of mitral inflow in patients undergoing cardiac resynchronization therapy. Am J Cardiol. 2006;98(6):780\u20135.","journal-title":"Am J Cardiol"},{"issue":"4","key":"1463_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.amjcard.2005.08.076","volume":"97","author":"AH Jansen","year":"2006","unstructured":"Jansen AH, Bracke FA, van Dantzig JM, et al. Correlation of echo-Doppler optimization of atrioventricular delay in cardiac resynchronization therapy with invasive hemodynamics in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2006;97(4):552\u20137.","journal-title":"Am J Cardiol"},{"issue":"21","key":"1463_CR12","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140\u201350.","journal-title":"N Engl J Med"},{"issue":"14","key":"1463_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329\u201338.","journal-title":"N Engl J Med"},{"issue":"25","key":"1463_CR14","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","volume":"363","author":"AS Tang","year":"2010","unstructured":"Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"25","key":"1463_CR15","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1161\/CIRCULATIONAHA.110.992552","volume":"122","author":"KA Ellenbogen","year":"2010","unstructured":"Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010;122(25):2660\u20138.","journal-title":"Circulation."},{"issue":"4","key":"1463_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ahj.2013.12.007","volume":"167","author":"J Brugada","year":"2014","unstructured":"Brugada J, Brachmann J, Delnoy PP, et al. Automatic optimization of cardiac resynchronization therapy using SonR-Rationale and design of the clinical trial of the SonRtip lead and automatic AV-VV optimization algorithm in the paradym RF SonR CRT-D (RESPOND CRT) trial. Am Heart J. 2014;167(4):429\u201336.","journal-title":"Am Heart J"},{"issue":"9","key":"1463_CR17","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1002\/clc.23616","volume":"44","author":"Y Su","year":"2021","unstructured":"Su Y, Hua W, Shen F, et al. Left ventricular-only fusion pacing versus cardiac resynchronization therapy in heart failure patients: a randomized controlled trial. Clin Cardiol. 2021;44(9):1225\u201332.","journal-title":"Clin Cardiol"},{"issue":"8 Pt 1","key":"1463_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jcmg.2018.02.014","volume":"12","author":"ZI Whinnett","year":"2019","unstructured":"Whinnett ZI, Sohaib SMA, Mason M, et al. Multicenter randomized controlled crossover trial comparing hemodynamic optimization against echocardiographic optimization of AV and VV delay of cardiac resynchronization therapy: the BRAVO trial. JACC Cardiovasc Imaging. 2019;12(8 Pt 1):1407\u201316.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1463_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijcard.2016.06.203","volume":"221","author":"G Coppola","year":"2016","unstructured":"Coppola G, Ciaramitaro G, Stabile G, et al. Magnitude of QRS duration reduction after biventricular pacing identifies responders to cardiac resynchronization therapy. Int J Cardiol. 2016;221:450\u20135.","journal-title":"Int J Cardiol"},{"key":"1463_CR20","doi-asserted-by":"crossref","unstructured":"Jing M. Association between changes in QRS width and echocardiographic responses to cardiac resynchronization therapy: a systematic review and meta-analysis. Medicine. 2020;99(2).","DOI":"10.1097\/MD.0000000000018684"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-022-01463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-022-01463-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-022-01463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:03:47Z","timestamp":1697148227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-022-01463-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1007\/s10840-022-01463-y","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority and complies with the Helsinki declaration. The requirement of signed informed consent for this retrospective study was waived by the Swedish Ethical Review Authority.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"RB has received speaker\u2019s fees from Medtronic, Abbott, and Biotronik, and has research grants from Boston Scientific. DM has received advisory board fees and speaker fees from Abbott and Medtronic. The other authors have no conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}